Publications by authors named "Connor A Ott"

Claim this Profile
T
Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models.
Connor A Ott, Timothy J Purwin, Pan-Yu Chen, Somenath Chowdhury, George L Mellor, Scott D Varney

Nat Commun· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell Death.
Sheera R Rosenbaum, Signe Caksa, Casey D Stefanski, Isabella V Trachtenberg, Haley P Wilson, Connor A Ott

Mol Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting TEAD-ious resistance.
Connor A Ott, Andrew E Aplin

Trends Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma.
McKenna Q Glasheen, Signe Caksa, Amelia G Young, Nicole A Wilski, Connor A Ott

Mol Cancer Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential recognition of canonical NF-κB dimers by Importin α3.
Tyler J Florio, Ravi K Lokareddy, Daniel P Yeggoni, Rajeshwer S Sankhala, Connor A Ott

Nat Commun· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inability to switch from ARID1A-BAF to ARID1B-BAF impairs exit from pluripotency and commitment towards neural crest formation in ARID1B-related neurodevelopmental disorders.
Luca Pagliaroli, Patrizia Porazzi, Alyxandra T Curtis, Chiara Scopa, Harald M M Mikkers, Connor A Ott

Nat Commun· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis